Skip to the page

Data / Drug companies / Imatinib mesylate

Imatinib mesylate: 17 companies and 36 products in the FDA NDC directory

Imatinib mesylate is listed in the FDA National Drug Code Directory by 17 companies, with 36 products in commercial distribution. 33 of the products (91.7%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, film coated; tablet, and the newest product started marketing on July 3, 2026.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Companies listing it
17
Products
36
Generic (ANDA) products
33 (91.7%)
Application numbers
9
Routes
Oral
Brand names
Gleevec
openFDA record search
api.fda.gov

Companies that list imatinib mesylate

Ranked by number of products. Finished drugs in commercial distribution.

CompanyProductsMain dosage formsMain marketing categoryNewest product started
BluePoint Laboratories4tablet, film coatedGeneric drugs (ANDA)December 6, 2024
Novartis Pharmaceuticals Corporation3tabletNew drug applications (NDA)December 23, 2014
Apotex Corp.2tablet, film coatedGeneric drugs (ANDA)August 5, 2016
Archis Pharma LLC2tabletGeneric drugs (ANDA)September 1, 2022
Armas Pharmaceuticals Inc.2tablet, film coatedGeneric drugs (ANDA)March 15, 2019
Ascend Laboratories, LLC2tablet, film coatedGeneric drugs (ANDA)February 1, 2019
Aurobindo Pharma Limited2tablet, film coatedGeneric drugs (ANDA)July 23, 2020
Camber Pharmaceuticals, Inc.2tablet, film coatedGeneric drugs (ANDA)April 14, 2025
Chartwell RX, LLC2tablet, film coatedGeneric drugs (ANDA)January 17, 2019
CivicaScript LLC2tablet, film coatedGeneric drugs (ANDA)July 3, 2026
Major Pharmaceuticals2tablet, film coatedGeneric drugs (ANDA)August 5, 2016
Qilu Pharmaceutical Co., Ltd.2tabletGeneric drugs (ANDA)June 21, 2022
Quallent Pharmaceuticals Health LLC2tablet, film coatedGeneric drugs (ANDA)September 1, 2023
Sun Pharmaceutical Industries, Inc.2tablet, film coatedGeneric drugs (ANDA)February 1, 2016
Teva Pharmaceuticals USA, Inc.2tablet, film coatedGeneric drugs (ANDA)August 4, 2016
Upsher-Smith Laboratories, LLC2tabletGeneric drugs (ANDA)May 17, 2024
American Health Packaging1tablet, film coatedGeneric drugs (ANDA)February 19, 2025

Dosage forms

Dosage formProductsShare
Tablet, film coated2775%
Tablet925%

Marketing categories

Marketing categoryProductsShare
Generic drugs (ANDA)3391.7%
New drug applications (NDA)38.3%

Pharmacologic classes

ClassProducts
Kinase Inhibitor36

Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.